Cardiologists

Different Prostacyclin Analogs Can Help Treat Pediatric PAH

Researchers provided a comprehensive overview of the advantages and drawbacks of prostacyclin and its analogs for the treatment of pulmonary arterial hypertension (PAH) in pediatric patients, as published in European Review for Medical and Pharmacological Sciences. “Epoprostenol can be effective against severe pulmonary hypertension,” the authors said. Iloprost, on the other hand, can treat severe…

SIRT3 Enzyme Could Help Develop New PAH Therapies

The sirtuin 3 (SIRT3) enzyme may prevent the development of cardiovascular diseases such as pulmonary arterial hypertension (PAH) by protecting the mitochondria, according to a new review published in Free Radical Biology and Medicine. Therefore, sirtuin 3 agonists may serve as potential treatments for cardiovascular diseases, the authors said. SIRT3 is a deacetylase that regulates…

Breathing Reserve at Peak Exercise May Not Provide IPAH Prognostic Value

Researchers discovered that patients’ breathing reserve at peak exercise was not associated with disease outcomes in idiopathic pulmonary arterial hypertension (IPAH), as published in the International Journal of Cardiology Congenital Heart Disease. In contrast, they found an association between breathing reserve >30% at peak exercise and improved survival rates in patients with Eisenmenger syndrome (EIS).…

Long-Term ERT for Older Adults With LOPD Can Have Variable Results

Researchers investigated the long-term effects of enzyme replacement therapy (ERT) in elderly patients with late-onset Pompe disease (LOPD) and concluded that it led to highly variable but satisfactory outcomes in motor and respiratory function, as published in Neuromuscular Disorders. Patients with LOPD have been treated with ERT such as recombinant human acid alpha-glucosidase (rhGAA), otherwise…

Psychosocial Factors Associated With Impaired Quality of Life in LCFAOD

Psychosocial factors, including higher anxiety levels and behavioral problems, significantly contributed to poorer quality of life (QoL) in children with inborn errors of metabolism such as long chain fatty acid oxidation disorder (LCFAOD). Diseases involving emergency restricted diets, higher parental anxiety, and diagnoses at younger ages also decreased QoL scores in these children, as published…

A Rare Case of VLCAD Deficiency With Severe Concurrent Conditions

Qatomah and colleagues presented a case study of a male patient with severe reversible acute rhabdomyolysis with concurrent hepatitis C infection and very long chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency, which is a type of long chain fatty acid oxidation disorder (LCFAOD), as published in the Journal of Medical Case Reports. Rhabdomyolysis is an adverse…

Newborn Screening May Predict Late-Onset Pompe Disease

A fifth of patients with late-onset Pompe disease identified through newborn screening developed symptoms after 15 years, according to a new study published in the Journal of Pediatrics. “[Newborn screening] was found to facilitate the early detection and early treatment of those subjects,” the researchers said. The study also found that although GAA variants c.[752C>T;761C>T]…

Newborn Screening May Improve VLCAD Deficiency Treatment

Data from the Swedish newborn screening (NBS) program suggested that patients with very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency who were diagnosed through the program had less severe phenotypes than those clinically diagnosed. VLCAD deficiency is a type of long chain fatty acid oxidation disorder (LCFAOD). “There is a clear difference between the clinically diagnosed patients…

Next post in DMD Insights